Non-small cell lung cancer (NSCLC) is commonly diagnosed at advanced stages limiting
treatment options. Although, targeted therapy has become integral part of NSCLC treatment …

Simple Summary Non-small-cell lung cancer is characterized by high morbidity and
mortality. Currently, the precision medicine approach in the adenocarcinoma subtype of non …

Background The differential outcomes of clinical studies of the targeted therapies for non-
small cell lung cancer (NSCLC) indicate that better stratification of patients is required. This …

In the light of current treatment developments for non-small cell lung cancer (NSCLC), the
idea of a plastic cellular tumorigenic network bound by key paracrine signaling pathways …

Objective: Patient-derived xenograft (PDX) models have shown great promise in preclinical
and translational applications, but their consistency with primary tumors in phenotypic …

Purpose: Current chemotherapeutic regimens have only modest benefit for non–small cell
lung cancer (NSCLC) patients. Cumulative toxicities/drug resistance limit chemotherapy …

Background Preclinical models that can better predict therapeutic activity in clinical trials are
needed in this era of personalized cancer treatment. Herein, we established genomically …

Simple Summary It is widely thought that tumors are composed of different subpopulations of
cancer cells carrying genetic alterations with some of them being common among all cells …

Introduction High fidelity between non–small cell lung cancer (NSCLC) primary tumours and
patient-derived tumour xenografts (PDTXs) is of paramount relevance to spur their …

New approaches to optimization of cancer drug development in the laboratory and the clinic
will be required to fully achieve the goal of individualized, precision cancer therapy …